Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation.

Autor:	Rocco JM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Mallarino-Haeger C; Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Randolph AH; Department of Medicine, George Washington University of Medicine and Health Sciences, Washington, DC, USA., Ray SM; Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Schechter MC; Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Zerbe CS; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Holland SM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Sereti I; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Aug 24; Vol. 75 (1), pp. e912-e915.
DOI:	10.1093/cid/ciab1024
Abstrakt:	The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential. (Published by Oxford University Press for the Infectious Diseases Society of America 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu